Year All2026202520242023 Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis August 20, 2026 Read more Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update August 14, 2026 Read more Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications August 4, 2026 Read more Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries July 21, 2026 Read more Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom June 11, 2026 Read more Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option May 18, 2026 Read more Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock April 30, 2026 Read more Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis April 29, 2026 Read more Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis March 3, 2026 Read more Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis January 20, 2026 Read more
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis August 20, 2026 Read more
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update August 14, 2026 Read more
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications August 4, 2026 Read more
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries July 21, 2026 Read more
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option May 18, 2026 Read more
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock April 30, 2026 Read more
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis April 29, 2026 Read more
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis March 3, 2026 Read more
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis January 20, 2026 Read more
